Short-term biodistribution and clearance of intravenously administered silica nanoparticles

Waegeneers, Nadia; Brasseur, Anne; Doren, Elke Van; Heyden, Sara Van der; Serreyn, Pieter-Jan; Pussemier, Luc; Mast, Jan; Schneider, Yves‐Jacques; Ruttens, Ann; Roels, Stefan

doi:10.1016/j.toxrep.2018.05.004

Cited by 42 publications

(24 citation statements)

References 29 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies also reported liver and spleen as target organs both after single and repeated intravenous exposure to SNPs. [41] Our results are consistent with other reports that showed smaller (13nm) mesoporous silica nanoparticles were conspicuously retained in the liver of male rats for up to 60 days. [42] Kumar et al also showed more accumulation of modified MSNPs (ORMOSIL)(20-25nm) in spleen, liver, and stomach than in kidney, heart, and lungs after intravenous injection.…”

Section: Histologysupporting

confidence: 93%

“…This could be due to the longer process of clearance of the larger Stöber SNPs from the liver due to reduced surface area. [41] Since most of the SNPs accumulated in liver and spleen, it is possible that the nanoparticles are either taken up by phagocytic cells in the blood or accumulated in liver and spleen resident macrophages for further clearance. This long-term silica nanoparticle stability in macrophages was reported before.…”

Section: Histologymentioning

confidence: 99%

See 1 more Smart Citation

Subchronic toxicity of silica nanoparticles as a function of size and porosity

Mohammadpour

Yazdimamaghani

Cheney

et al. 2019

Journal of Controlled Release

View full text Add to dashboard Cite

Despite increasing reports of using silica nanoparticles (SNPs) for controlled drug delivery applications, their long-term toxicity profile following intravenous administration remains unexplored. Herein, we investigated the acute (10-day) and subchronic (60-day and 180-day) toxicity of nonporous SNPs of approximately 50 nm (Stöber SNPs50) and approximately 500 nm in diameter (Stöber SNPs500), and mesoporous SNPs of approximately 500 nm in diameter (MSNPs500) upon single-dose intravenous injection into male and female immune-competent inbred BALB/C mice. The Maximum Tolerated Dose (MTD) of the particles was determined 10 days post-injection. The MTD of SNPs was administered and toxicity evaluated over 60 and 180 days. Results demonstrate that Stöber SNPs50 exhibit systemic toxicity with MTD of 103 ± 11 mg.kg −1 for female and 100 ± 6 mg.kg −1 for male mice, respectively. Toxicity was alleviated by increasing the size of the particles (Stöber SNPs500). MTD values of 303 ± 4 mg.kg −1 for female and 300 ± 13 mg.kg −1 for male were observed for Stöber SNPs500. Mesoporous SNPs500 showed considerable systemic sex-related toxicity, with MTDs ranging from 40 ± 2 mg.kg −1 to 95 ± 2 mg.kg −1 for male and female mice, respectively. Studies of SNPs showed blood toxicity as a function of physiochemical properties such as significant differences in the mean corpuscular hemoglobin (MCHC) and platelet number at day 10 and white blood cell count at day 60. Histological examination also showed size-, porosity-and time-dependent tissue toxicity. Stöber

show abstract

Section: Histologysupporting

confidence: 93%

Section: Histologymentioning

confidence: 99%

Subchronic toxicity of silica nanoparticles as a function of size and porosity

Mohammadpour

Yazdimamaghani

Cheney

et al. 2019

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…Aggregates of macrophages or microgranulomes increased between 6 and 24 h after silica nanoparticle administration. Clearance of silica nanoparticles from the liver appears to be slower than from the spleen, probably due to hepatic processing and biliary excretion (98).…”

Section: As Shown Inmentioning

confidence: 99%

“…Different pharmacokinetic models such as compartmental and especially physiologically based pharmacokinetic (PBPK) models have been developed to characterize the disposition of drugs in different organs and tissues, and especially in the liver, when they are administered in different types of nanoparticles (98,(106)(107)(108)(109)(110)(111)(112).…”

Section: Pharmacokinetic Modelsmentioning

confidence: 99%

Targeting of Hepatic Macrophages by Therapeutic Nanoparticles

2020

View full text Add to dashboard Cite

“…The excretion of NMs is the final step of their metabolic kinetics in vivo, which is closely related with their distribution. For instance, intravenously and subcutaneously injected SiNPs accumulate in the liver and are primarily eliminated through hepatic processing and excreted via the biliary or feces route [89,90]. Interestingly, Qi et al [91] found that a majority of GO nanoplatelets (GONPs) and oxidized multiwalled carbon nanotubes (oMWCNTs) were excreted through feces after respective intravenous administration, while coexposure to both NMs led to urine excretion.…”

Section: Distribution and Metabolism Of Nms In Vivomentioning

confidence: 99%

Nanomaterial-mediated autophagy: coexisting hazard and health benefits in biomedicine

Feng

Zhang

et al. 2020

Part Fibre Toxicol

View full text Add to dashboard Cite

Background Widespread biomedical applications of nanomaterials (NMs) bring about increased human exposure risk due to their unique physicochemical properties. Autophagy, which is of great importance for regulating the physiological or pathological activities of the body, has been reported to play a key role in NM-driven biological effects both in vivo and in vitro. The coexisting hazard and health benefits of NM-mediated autophagy in biomedicine are nonnegligible and require our particular concerns. Main body We collected research on the toxic effects related to NM-mediated autophagy both in vivo and in vitro. Generally, NMs can be delivered into animal models through different administration routes, or internalized by cells through different uptake pathways, exerting varying degrees of damage in tissues, organs, cells, and organelles, eventually being deposited in or excreted from the body. In addition, other biological effects of NMs, such as oxidative stress, inflammation, necroptosis, pyroptosis, and ferroptosis, have been associated with autophagy and cooperate to regulate body activities. We therefore highlight that NM-mediated autophagy serves as a double-edged sword, which could be utilized in the treatment of certain diseases related to autophagy dysfunction, such as cancer, neurodegenerative disease, and cardiovascular disease. Challenges and suggestions for further investigations of NM-mediated autophagy are proposed with the purpose to improve their biosafety evaluation and facilitate their wide application. Databases such as PubMed and Web of Science were utilized to search for relevant literature, which included all published, Epub ahead of print, in-process, and non-indexed citations. Conclusion In this review, we focus on the dual effect of NM-mediated autophagy in the biomedical field. It has become a trend to use the benefits of NM-mediated autophagy to treat clinical diseases such as cancer and neurodegenerative diseases. Understanding the regulatory mechanism of NM-mediated autophagy in biomedicine is also helpful for reducing the toxic effects of NMs as much as possible.

show abstract

Short-term biodistribution and clearance of intravenously administered silica nanoparticles

Abstract: Graphical abstract

Cited by 42 publications

References 29 publications

Subchronic toxicity of silica nanoparticles as a function of size and porosity

Subchronic toxicity of silica nanoparticles as a function of size and porosity

Targeting of Hepatic Macrophages by Therapeutic Nanoparticles

Nanomaterial-mediated autophagy: coexisting hazard and health benefits in biomedicine

Contact Info

Product

Resources

About